Although direct evidence of the interaction between BRD4 and the IGF2BP3 promoter/enhancer was not provided in our study, analysis of BRD4 chromatin immunoprecipitation sequencing in the K562 leukemia cell line identified potential binding sites upstream of the transcription start site of IGF2BP3 expression, supporting the role of BRD4 in controlling IGF2BP3 transcription. Here, IGF2BP3 is linked to leukemia.